Corrigendum to: Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure
Araki K, Ishid N, Horii R, Takahashi S, Akiyama F, Ito Y, Ohno S. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure. Expert Opinion on Pharmacotherapy 2015; 16(17):2561-2568.
When the above article was first published online, figure 1 was published with errors.
‘Non-steroidal anti-inflammatories’ has now been corrected to read ‘Non-steroidal aromatase inhibitor’. ‘Steroidal anti-inflammatories’ has now been corrected to read ‘Steroidal aromatase inhibitor’.